Aclaris Therapeutics (ACRS) Stock Climbs On R&D Day!

Aclaris ACRS Stock News

Aclaris Therapeutics Inc (NASDAQ: ACRS) is rocketing on high volume this morning, trading on early gains of more than 50%. The gains come after the company announced that it will be holding an R&D day, exciting investors. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ACRS Heads Up On R&D Day

In a press release issued early this morning, Aclaris Therapeutics announced that it will be holding an R&D day. The event will be centered around analysts and investors, updating those interested with regard to its pipeline of novel drug candidates for immuno-inflammatory diseases.

In the release, ACRS said that the R&D Day event will be held on Friday, September 27, 2019 from 8:00 AM to 11:00 AM. The event will be held in New York City.

The comapny said that it will discuss the following topics during the event:

  • Its drug discovery engine, known as the KINect Platform.
  • Its oral alternative to injectable anti-cytokine biologics and JAK inhibitors for immuno-inflammatory diseases. This is a product known as ATI-450, an MK2 inhibitor.
  • Its “soft” topical JAK 1/3 inhibitor, known as ATI-1777.
  • Its ITK/TXK/JAK3 inhibitor of autoimmune disease, known as ATI-2138.
  • Finally, the company will discuss its gut restricted inhibitors of ITK and/or JAK kinases as drugs for inflammatory bowel disease.

If you can’t make it to New York for the event, you don’t have to miss the news. ACRS said that those interested who cannot physically attend, can attend virtually by logging on to the Investors page of its website prior to the event.

Those that have scheduling conflicts can catch the news via a replay of the webcast, which will be archived on the company’s website for 30 days following the call. Those who would like to attend physically can email to RSVP.

Why Investors Are So Excited

The truth of the matter is that Aclaris Therapeutics investors are looking for updates on several topics. However, with the press release, the company hit the nail on the head.

Just about every topic on which investors want to see an update is listed. Of course, it is expected that the R&D day will uncover quite a bit of positive information, that could send the stock heading even higher.

So, there may be more room to run with ACRS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.